Analysis: Diclofenac's heart risks warrant caution

02/14/2013 | TheHeart.org (Montreal) (free registration)

Diclofenac, a nonsteroidal anti-inflammatory drug, was associated with an up to 63% higher risk of cardiovascular events, and should be eliminated from essential-medicines lists, according to a meta-analysis published online in PLoS Medicine. Diclofenac was the most widely used NSAID in 15 countries, and its heart risk was comparable to that of rofecoxib, which was withdrawn from the market due to its cardiovascular toxocicty.

View Full Article in:

TheHeart.org (Montreal) (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA